Shares of Valeritas Holdings Inc (NASDAQ:VLRX) have received a consensus rating of “Buy” from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $2.67.

Several equities analysts have recently issued reports on the company. BTIG Research assumed coverage on Valeritas in a research note on Tuesday, December 4th. They set a “buy” rating and a $1.00 target price on the stock. Oppenheimer set a $2.00 target price on Valeritas and gave the company a “buy” rating in a research note on Wednesday, November 21st. Finally, Zacks Investment Research cut Valeritas from a “buy” rating to a “hold” rating in a research note on Tuesday, February 12th.

VLRX opened at $0.39 on Thursday. The company has a debt-to-equity ratio of 2.82, a quick ratio of 3.98 and a current ratio of 4.47. Valeritas has a 52-week low of $0.30 and a 52-week high of $4.58. The company has a market cap of $9.98 million, a PE ratio of -0.23 and a beta of 2.10.

In other Valeritas news, major shareholder Armistice Capital Master Fund bought 150,000 shares of Valeritas stock in a transaction dated Thursday, December 20th. The shares were purchased at an average cost of $0.34 per share, with a total value of $51,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.80% of the stock is currently owned by insiders.

Hedge funds have recently modified their holdings of the stock. Weiss Multi Strategy Advisers LLC purchased a new stake in Valeritas in the fourth quarter worth $41,000. Geode Capital Management LLC grew its stake in Valeritas by 138.0% in the fourth quarter. Geode Capital Management LLC now owns 186,971 shares of the company’s stock worth $60,000 after purchasing an additional 108,416 shares during the period. Northern Trust Corp grew its stake in Valeritas by 855.4% in the fourth quarter. Northern Trust Corp now owns 185,469 shares of the company’s stock worth $60,000 after purchasing an additional 166,057 shares during the period. Millennium Management LLC purchased a new stake in Valeritas in the fourth quarter worth $165,000. Finally, Renaissance Technologies LLC grew its stake in Valeritas by 730.3% in the third quarter. Renaissance Technologies LLC now owns 163,650 shares of the company’s stock worth $218,000 after purchasing an additional 143,940 shares during the period.

Valeritas Company Profile

Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. It offers V-Go, a wearable insulin delivery device for basal-bolus therapy. The company also develops h-Patch, a controlled delivery technology platform; Mini-Ject technology for needle-free injection systems; and Micro-Trans technology for microneedle design, fabrication, and drug delivery.

Recommended Story: Market Capitalization in the Stock Market

Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.